Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Conditions: Salivary Gland Neoplasm Duct Interventions: Drug: Rezvilutamide; Drug: Leuprolide Acetate Sponsors: Peking University First Hospital; Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials